Cargando…

Effect of evidence-based therapy for secondary prevention of cardiovascular disease: Systematic review and meta-analysis

BACKGROUND: The combination pharmacotherapy of antiplatelet agents, lipid-modifiers, ACE inhibitors/ARBs and beta-blockers are recommended by international guidelines. However, data on effectiveness of the evidence-based combination pharmacotherapy (EBCP) is limited. OBJECTIVES: To determine the eff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Tian-Tian, Wong, Ian C. K., Man, Kenneth K. C., Chen, Yang, Crake, Thomas, Ozkor, Muhiddin A., Ding, Ling-Qing, Wang, Zi-Xuan, Zhang, Lin, Wei, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338367/ https://www.ncbi.nlm.nih.gov/pubmed/30657781 http://dx.doi.org/10.1371/journal.pone.0210988

Ejemplares similares

Endothelium-Derived Hyperpolarizing Factor and Vascular Function
por: Ozkor, Muhiddin A., et al.
Publicado: (2011)

The effect of telemedicine on secondary prevention of atherosclerotic cardiovascular disease: A systematic review and meta-analysis
por: Deng, Liangying, et al.
Publicado: (2022)

Secondary cardiovascular prevention in older adults: an evidence based review
por: Damluji, Abdulla A, et al.
Publicado: (2015)

Impact of multiple cardiovascular medications on mortality after an incidence of ischemic stroke or transient ischemic attack
por: Ma, Tian-Tian, et al.
Publicado: (2021)

Correction to: Impact of multiple cardiovascular medications on mortality after an incidence of ischemic stroke or transient ischemic attack
por: Ma, Tian-Tian, et al.
Publicado: (2021)

Inequalities in the use of secondary prevention of cardiovascular disease by socioeconomic status: evidence from the PURE observational study
por: Murphy, Adrianna, et al.
Publicado: (2018)

Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a)
por: Grützmacher, P., et al.
Publicado: (2017)

Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials
por: de Jong, Marit, et al.
Publicado: (2017)

Diabetes: how to manage cardiovascular risk in secondary prevention patients
por: Anderson, Sarah L, et al.
Publicado: (2022)

Smartphones in the secondary prevention of cardiovascular disease: a systematic review
por: Hamilton, Sandra J., et al.
Publicado: (2018)

Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention
por: Toth, Peter P., et al.
Publicado: (2023)

Risk factors in cardiovascular patients: Challenges and opportunities to improve secondary prevention
por: Gabulova, Rahima, et al.
Publicado: (2023)

Secondary Prevention of Cardiovascular Disease in Women: Closing the Gap
por: Thakkar, Aarti, et al.
Publicado: (2021)

Effective dosing of L-carnitine in the secondary prevention of cardiovascular disease: a systematic review and meta-analysis
por: Shang, Ruiping, et al.
Publicado: (2014)

PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis
por: Wang, Xing, et al.
Publicado: (2022)

Prevalence of cardiovascular medication on secondary prevention after myocardial infarction in China between 1995-2015: A systematic review and meta-analysis
por: Zhao, Min, et al.
Publicado: (2017)

Secondary Preventive Care for Cardiovascular Diseases in Bangladesh: A National Survey
por: Alam, Sayed Ibn, et al.
Publicado: (2021)

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
por: Mahaffey, Kenneth W., et al.
Publicado: (2018)

Predicting major adverse cardiovascular events for secondary prevention: protocol for a systematic review and meta-analysis of risk prediction models
por: Akyea, Ralph K, et al.
Publicado: (2020)

Antipsychotic Medication and Risk of Incident Seizure in People with Autism Spectrum Disorder: Analyses with Cohort and Within Individual Study Designs
por: Alfageh, Basmah H., et al.
Publicado: (2021)

Thrombus Burden and Outcomes in Patients With COVID-19 Presenting With STEMI Across the Pandemic
por: Rathod, Krishnaraj S., et al.
Publicado: (2023)

Nurses' perspectives on nurse-coordinated prevention programmes in secondary prevention of cardiovascular disease: a pilot survey
por: Jorstad, H.T., et al.
Publicado: (2015)

Allopurinol for Secondary Prevention in Patients with Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Ye, Yuyang, et al.
Publicado: (2023)

Secondary Prevention of Cardiovascular Diseases and Application of Technology for Early Diagnosis
por: Karunathilake, Sachith Paramie, et al.
Publicado: (2018)

Cost-Effectiveness of Aspirin Adherence for Secondary Prevention of Cardiovascular Events
por: Djatche, Laurence M., et al.
Publicado: (2018)

Targeted proteomics improves cardiovascular risk prediction in secondary prevention
por: Nurmohamed, Nick S., et al.
Publicado: (2022)

Different inflammatory pathways underlying cardiovascular risk in secondary prevention( )
por: Nurmohamed, Nick S, et al.
Publicado: (2022)

Challenging the “Divinity” of Aspirin Monotherapy for Secondary Prevention of Cardiovascular Disease
por: Spartalis, Michael, et al.
Publicado: (2023)

Prize Question of the Lyceum Medicum Londinense
por: Crake, John
Publicado: (1799)

Emerging evidence for the use of colchicine for secondary prevention of coronary heart disease
por: Nidorf, Stefan M, et al.
Publicado: (2022)

Use of Aspirin for Primary and Secondary Cardiovascular Disease Prevention in the United States, 2011–2012
por: Mainous, Arch G., et al.
Publicado: (2014)

Serum Leptin and Adiponectin: Indicators of Cardiovascular Disease Secondary to Psoriasis
por: Yan, Haoxiang, et al.
Publicado: (2022)

Cardiovascular disease risk and secondary prevention of cardiovascular disease among patients with low health literacy
por: van Schaik, T. M., et al.
Publicado: (2017)

Efficacy of Standard and Intensive Statin Treatment for the Secondary Prevention of Cardiovascular and Cerebrovascular Events in Diabetes Patients: A Meta-Analysis
por: de Vries, Folgerdiena M., et al.
Publicado: (2014)

Efficacy and Safety of Colchicine in Prevention of Secondary Cardiovascular Outcomes Among Patients With Coronary Vessel Disease: A Meta-Analysis
por: Sattar, Lubna, et al.
Publicado: (2022)

Physical activity in primary and secondary prevention of cardiovascular disease: Overview updated
por: Alves, Alberto J, et al.
Publicado: (2016)

The Availability and Affordability of Cardiovascular Medicines for Secondary Prevention in Tehran Province (Iran)
por: Vasheghani Farahani, Ali, et al.
Publicado: (2018)

Cardiac rehabilitation and its essential role in the secondary prevention of cardiovascular diseases
por: Winnige, Petr, et al.
Publicado: (2021)

Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe
por: Grigorian-Shamagian, Lilian, et al.
Publicado: (2021)

Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
por: Michaeli, Daniel Tobias, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v5h1afuokm2a219ls02g5lb6sp